US Centers for Disease Control
Multistate outbreak of hemolysis in hemodialysis patients -
Nebraska and Maryland, 1998
Morb Mortal Weekly Rep
(Jun) 47:No.23 1998

Reproduced from the .pdf version of the MMWR June 19, 1998, which is
available at
this site.
Multistate Outbreak of Hemolysis in Hemodialysis Patients -
Nebraska and Maryland, 1998
From May 13 through May 23, 1998, a total of 30 patients in three states*
developed
hemolysis with or without chest pains, shortness of breath, nausea, or
abdominal pain
while undergoing hemodialysis (HD). Two patients died. This report summarizes
the
preliminary findings of investigations in Nebraska and Maryland and
implicated lot
number 04015309 of Cobe Centrysystem 3 Blood Tubing sets (Gambro Healthcare,
Lakewood, Colorado)** as the cause of these reactions.
Nebraska
A case was defined as hypertension (an increase of > 30 mm Hg from the
baseline
systolic blood pressure) and evidence of hemolysis (i.e., positive “pink
test” [pink-appearing
serum]) in a patient within 12 hours of initiating hemodialysis during
May 13-20. A total of 13 (11%) of 118 patients at two HD centers in Lincoln,
Nebraska,
had illnesses that met the case definition. In addition, case-patients
reported chest
pain (five), shortness of breath (four), nausea (four), abdominal pain
(four), vomiting
(three), back pain (two), cyanosis (two), or diarrhea (one). Onset of
symptoms occurred
a median of 120 minutes (range: 20-272 minutes) into the dialysis session.
Case-patients ranged in age from 46 to 84 years (median: 70 years); seven
were
men. They had received hemodialysis for a median of 3 years (range: <1 to
8 years);
11 (85%) used reprocessed dialyzers. Of the 13 patients, 11 (85%) required
hospitalization;
four (31%), admission to an intensive-care unit (ICU); and three (23%),
blood
transfusion. The 13 case-patients were dialyzed on 12 different machines but
all may
have been dialyzed using a Cobe Centrysystem 3 Blood Tubing Set (lot number
04D15309) that was present at the clinic during the dialysis period. During
hemodialysis,
lot numbers of blood tubing are not routinely recorded. However, for six case
-patients,
the blood tubing lot number was 04D15309.
Examination of the implicated blood tubing revealed narrowing of the
aperture
through which blood was pumped during the dialysis treatment. Analyses of
the
water supply at one of the HD centers was within normal limits for chlorine,
chloramine, endotoxin, bacteria, and trace element levels as set by the
American Association
for the Advancement of Medical Instrumentation.
Maryland
During May 18-23, a total of 12 (4%) of 298 patients at four HD centers in
Baltimore
developed abdominal pain (eight), nausea (seven), and/or erythroderma (four);
all had
evidence of hemolysis on admission to the hospital. Onset of symptoms
occurred a
median of 114 minutes (range: 22-227 minutes) into the dialysis session.
Case-patients ranged in age from 48 to 85 years (median: 67 years); seven
were
men. Case-patients had received hemodialysis for a median of 3 years (range:
1 to
>5 years); none used reprocessed dialyzers. All case-patients required
hospitalization;
four, admission to ICU; and six, blood transfusion. The 12 case-patients were
dialyzed
on 12 different machines, but all may have been dialyzed using a Cobe
Centrysystem
3 Blood Tubing Set (lot number 04D15309) that was present at the clinic
during the
dialysis period.
*No data were available for five patients in Massachusetts.
**Use of trade names and commercial sources is for identification only and
does not imply
endorsement by CDC or the U.S. Department of Health and Human Services.
Vol. 47 / No. 23 MMWR 483
On May 25, the manufacturer issued a voluntary nationwide recall of specific
lots of
catalog number 003210-500 (including lot number 04D15309) of Cobe
Centrysystem 3
Blood Tubing sets. On June 10, following additional reports (including two
additional
deaths) in Alabama and New Jersey, the manufacturer expanded the recall to
all lots
of Cobe Centrysystem 3 Blood Tubing sets and Cobe Hemodialysis kits
containing
blood tubing sets for dialysis with catalog numbers 003109-400, 003109-410,
003110-
500, 003111-500, 003112-500, 003113-500, 003114-500, 003210-500, 003212-500,
003101-000, and 003212-515.
Reported by: L Spry, MD, A Stivers, Dialysis Center of Lincoln, Lincoln; R
Morin, MD, Bryan
Memorial Hospital, Lincoln; T Timmons, S Weaver, C Douglas, Lincoln-Lancaster
County Health
Dept, Lincoln; T Safranek, MD, State Epidemiologist, Nebraska Health and
Human Svcs System.
J Roche, MD, C Groves, MS, D Portesi, MPH, M Hawkins, MD, D Dwyer, MD, State
Epidemiolo
gist, Maryland Dept of Health and Mental Hygiene. Center for Devices and
Radiologic Health,
and Office of Regulatory Affairs, Food and Drug Administration. Div of
Chronic Disease Control
and Prevention, National Center for Chronic Disease Prevention and Health
Promotion; Interna
tional Emergency and Refugee Health Program, National Center for
Environmental Health;
Hospital Infections Program, National Center for Infectious Diseases; and EIS
officers, CDC.
Editorial Note:
In the United States, approximately 225,000 persons with end stage
renal disease undergo long-term hemodialysis each year (1). Hemolysis (i.e.,
premature
breakdown of red blood cells [RBCs]) associated with hemodialysis is rare
(2,3) . The most frequent causes of hemodialysis-associated hemolysis are
increased
chloramine in the water used for dialysis; nitrate contamination of the
dialysate, formaldehyde
residue left after dialyzer reprocessing or water treatment system
disinfection,
use of hypotonic dialysate or dialysate exceeding 108 degrees F (42 degrees
C), or mechanical
injury of RBCs from occluded or kinked hemodialysis blood lines (2-4).
In this outbreak, all episodes of hemolysis have been associated with blood
tubing
produced by a single manufacturer. Preliminary findings suggest that the
narrowed
aperture of the blood tubing sets caused mechanical lysis of the RBCs.
To ascertain the extent of this problem, all episodes of hemolysis in
dialysis patients
using a Cobe Centrysystem 3 Blood Tubing Set or Cobe Hemodialysis Kit should
be reported through state health departments to CDC's Hospital Infections
Program,
National Center for Infectious Diseases, telephone (404) 639-6413, and to the
Food and
Drug Administration's MedWatch program, telephone (800) 332-1088.
References
1. Health Care Financing Administration. ESRD facility survey data, 1995.
Washington, DC: US
Department of Health and Human Services, 1995.
2. Sweet SJ, McCarthy S, Steingart R, Callahan T. Hemolytic reactions
mechanically induced by
linked hemodialysis lines. Am J Kidney Dis 1996;27:262-6.
3. Corea AL, Ohanian N, Anderson M, Holloway M. Hemodialysis procedure. In:
Nissenson AR,
Fine RN, Gentile DE, eds. Clinical dialysis. Norwalk, Connecticut, and San
Mateo, California:
Appleton and Lange, 1990:147-160.
4. Fried W. Hematologic aspects of uremia. In: Nissenson AR, Fine RN, Gentile
DE, eds. Clinical
dialysis. Norwalk, Connecticut, and San Mateo, California: Appleton and
Lange, 1990:391-408.